

| Corresponding author(s):   | Kenji Miura  |
|----------------------------|--------------|
| Last updated by author(s): | Dec 13, 2019 |

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| Chariatia  |  |  |  |  |
|--|--|--|--|--|
| Statistics   |  |  |  |  |
|  | r all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.  |  |  |  |
| n/a Confirmed  |  |  |  |  |
|  | mple size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement  |  |  |  |
|  | on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |  |  |  |
| The statistica Only common   | The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.  |  |  |  |
| A description  | of all covariates tested   |  |  |  |
| A description  | of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |  |  |  |
| A full descrip   | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficier AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)         |  |  |  |
| For null hypo  | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.                              |  |  |  |
| For Bayesian   | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings   |  |  |  |
| For hierarchi  | cal and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |  |  |  |
| Estimates of   |  |  |  |  |
| —,—  | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.  |  |  |  |
| Software and   | code   |  |  |  |
| Policy information abo   | out availability of computer code  |  |  |  |
| Data collection  | no software was used.  |  |  |  |
| Data analysis  | Statistical analysis was done by Excel 2016 and IBM SPSS Statistics.   |  |  |  |
| ,  | tom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.   |  |  |  |
|  | deposition in a community repository (e.g. GitHub). See the Nature Research <u>guidelines for submitting code &amp; software</u> for further information.  |  |  |  |
| Data   |  |  |  |  |
| Policy information abo   | out <u>availability of data</u>  |  |  |  |
| - Accession codes, ui<br>- A list of figures that  | include a <u>data availability statement</u> . This statement should provide the following information, where applicable:<br>nique identifiers, or web links for publicly available datasets<br>thave associated raw data<br>y restrictions on data availability |  |  |  |
| All data supporting the findings of this study are available within the paper and its supplementary information files                                |  |  |  |  |
|  |  |  |  |  |
| Field-specific reporting   |  |  |  |  |
| Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. |  |  |  |  |
| Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences  |  |  |  |  |

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

## Life sciences study design

| All studies must disclose on these points even when the disclosure is negative. |  |  |  |  |  |
|---|--|--|--|--|--|
| Sample size   | Sample size is provided in each figure legend. The sample size was chosen based on the data previously reported for each experiments.                      |  |  |  |  |
| Data exclusions   | No data was excluded.  |  |  |  |  |
| Replication   | At least three independent replication was done.   |  |  |  |  |
| Randomization   | Not applicable.  |  |  |  |  |
| Blinding  | Investigators were not blinded to Arabidopsis genotypes during experiments.  Each sample group with different genotypes was labeled but treated at random. |  |  |  |  |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods                   |  |
|----------------------------------|---------------------------|--|
| n/a Involved in the study        | n/a Involved in the study |  |
| Antibodies                       | ChIP-seq                  |  |
| Eukaryotic cell lines            | Flow cytometry            |  |
| Palaeontology                    | MRI-based neuroimaging    |  |
| Animals and other organisms      | ·                         |  |
| Human research participants      |                           |  |
| Clinical data                    |                           |  |
|                                  |                           |  |

## **Antibodies**

| Antibodies used | Anti-GST antibody (Abcam), anti-DYKDDDDK antibody (Wako), anti-Maltose binding protein antibody (New England Biolabs) |  |
|-----------------|---|--|
| Validation      | We followed manufactures' description.  |  |